

## *Neisseria gonorrhoeae* MtrCDE Efflux Pump During *In Vivo* Experimental Genital Tract Infection in Men and Mice Reveals the Presence of Within-Host Colonization Bottleneck

1 Andreea Waltmann<sup>1</sup>, Jacqueline T. Balthazar<sup>2</sup>, Afrin A. Begum<sup>3</sup>, Nancy Hua<sup>4</sup>, Ann E. Jerse<sup>3</sup>,  
2 William M. Shafer<sup>2,5,6</sup>, UNC-Global Clinical Trials Unit/DMID 09-0106 Study Team<sup>7</sup>, Marcia  
3 M. Hobbs<sup>1,8\*</sup>, Joseph A. Duncan<sup>1,9,10\*</sup>

4  
5 <sup>1</sup> Division of Infectious Diseases, Department of Medicine, School of Medicine, University of North  
6 Carolina, Chapel Hill, NC, United States

7 <sup>2</sup> Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia,  
8 United States

9 <sup>3</sup> Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland,  
10 United States

11 <sup>4</sup> The Emmes Corporation, Rockville, Maryland, United States

12 <sup>5</sup> The Emory Antibiotic Resistance Center, Emory University School of Medicine, Atlanta, Georgia,  
13 United States

14 <sup>6</sup> Laboratories of Bacterial Pathogenesis, Veterans Affairs Medical Center (Atlanta), Decatur, Georgia,  
15 United States

16 <sup>7</sup> See Supplemental Acknowledgments for , UNC-Global Clinical Trials Unit/DMID 09-0106 Study  
17 Team member details

18 <sup>8</sup> Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill,  
19 North Carolina, United States

20 <sup>9</sup> Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC,  
21 United States

22 <sup>10</sup> Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC,  
23 United States

24 \* Co-senior authors contributed equally

Address correspondence to: Joseph A. Duncan, Division of Infectious Diseases (Campus Box 7030), 130  
Mason Farm Road, Chapel Hill, NC, 27599-7030, USA.; Phone: 1 (919) 843-0715 Email:  
[jaduncan@med.unc.edu](mailto:jaduncan@med.unc.edu)

### Conflict-of-interest statement

The authors have declared that no conflict of interest exists.

25 **Abstract**

26 The MtrCDE efflux pump of *Neisseria gonorrhoeae* exports a wide range of antimicrobial  
27 compounds that the gonococcus encounters at mucosal surfaces during colonization and  
28 infection. Here, we evaluate the role of this efflux pump system in strain FA1090 in human male  
29 urethral infection with a Controlled Human Infection Model. Using the strategy of competitive  
30 multi-strain infection with wild-type FA1090 and an isogenic mutant strain that does not contain  
31 a functional MtrCDE pump, we found that the presence of the efflux pump during human  
32 experimental infection did not confer a competitive advantage. This finding is in contrast to  
33 previous findings in female mice, which demonstrated that gonococci of strain FA19 lacking a  
34 functional MtrCDE pump had a significantly reduced fitness compared to the wild type strain in  
35 the lower genital tract of female mice. We conducted competitive infections in female mice with  
36 FA19 and FA1090 strains, including mutants that do not assemble a functional Mtr efflux pump,  
37 demonstrating the fitness advantage provided by the MtrCDE efflux pump during infection of  
38 mice is strain dependent. Our data indicate that new gonorrhea treatment strategies targeting the  
39 MtrCDE efflux pump functions may not be universally efficacious in naturally occurring  
40 infections. Owing to the equal fitness of FA1090 strains in men, our experiments unexpectedly  
41 demonstrated the likely presence of an early colonization bottleneck of *N. gonorrhoeae* in the  
42 human male urethra.

43 **TRIAL REGISTRATION.** Clinicaltrials.gov NCT03840811.

44

## 45 Introduction

46  
47 *Neisseria gonorrhoeae* is exquisitely adapted to humans, its only natural host. The gonococcus is  
48 equipped with multiple mechanisms that allow it to quickly respond to host innate immune  
49 responses. The multiple transferrable resistance (Mtr) phenotype was first identified in 1973 as  
50 providing decreased susceptibility of gonococci to structurally diverse hydrophobic antibiotics,  
51 detergents and dyes (1) and was postulated to be due to decreased permeability of the bacterial  
52 outer membrane to these antimicrobials (2). Over two decades later it was shown that the  
53 resistance phenotype was due to the relief of transcriptional repression of the *mtrCDE* –encoded  
54 efflux pump operon. The MtrCDE efflux pump is a member of the resistance-nodulation-  
55 division family possessed by many Gram-negative bacteria (3, 4). The MtrCDE pump is critical  
56 to the ability of *N. gonorrhoeae* to export a wide range of substrates that bathe mucosal surfaces,  
57 including host-derived antimicrobials (antimicrobial peptides, bile salts, progesterone, fatty  
58 acids, and cathelicidins, such as human LL-37 or its murine homologue CRAMP-38), and  
59 antibiotics (3, 5-10). The Mtr system has also been associated with enhanced resistance to killing  
60 by human neutrophils and neutrophil products (11).

61  
62 The *mtrCDE* operon is transcriptionally regulated by *cis*- and *trans*-acting control processes (5,  
63 12, 13). MtrD is the inner membrane component of the pump and is connected to MtrE in the  
64 outer membrane through the periplasmic membrane fusion lipoprotein MtrC (4, 6, 10). Efflux is  
65 dependent on energy supplied by the proton motive force transduced by MtrD (14, 15).  
66 Expression of *mtrCDE* in wild type gonococci is subject to repression by MtrR (7, 16, 17) and, in  
67 the presence of an inducer, activation by MtrA (17, 18). Loss-of-function *mtrD* mutations  
68 significantly reduce the ability of gonococci to colonize the lower genital tract of female mice in  
69 experimental infection (19). Higher levels of the pump, on the other hand, either through  
70 induction by MtrA, or de-repression through either loss of MtrR or through mutations in the Mtr  
71 DNA-binding region enhance resistance to antibiotics (8, 20-23), host-derived antimicrobials (8),  
72 and *in vivo* fitness in the mouse infection model (24). In strains that overexpress the pump, loss  
73 of MtrCDE can increase antibiotic susceptibility in otherwise clinically-resistant gonococci (25),  
74 including strain H041, which was isolated from the first reported extended-spectrum-  
75 cephalosporin resistant case of gonorrhea (26). These findings support the idea that the MtrCDE  
76 efflux pump is important during *in vivo* infection (8, 24).

77  
78  
79 We hypothesized that mutations that abrogate the expression of the Mtr efflux pump would  
80 affect *N. gonorrhoeae* infectivity in experimentally infected human males. We and others have  
81 developed a model of experimental human gonococcal infection (reviewed in (27, 28)), which  
82 takes advantage of the self-limited nature of gonococcal urethral infection in men. Infection can  
83 be initiated in male participants through intraurethral inoculation, and this model has proven to  
84 be a safe and efficient means of studying human urethral gonococcal infection without  
85 serious complications (27, 28). With this model and the strategy of competitive infections  
86 initiated by a mixture of wild type strain FA1090 and an isogenic FA1090 mutant that lacks  
87 MtrD, we sought to measure the importance of the MtrCDE efflux pump on *N. gonorrhoeae*  
88 during experimental urethral infection of human males.

89

## 90 Results

91

### 92 Infectivity and clinical courses of infection in non-competitive infections

93 The genotypes of inoculating strains are shown in Table 1. Results are summarized in Table 2.  
94 The evaluable population included participants who received a dose of *N. gonorrhoeae* within 1  
95 log of the intended dose of one million organisms [i.e.  $\text{Log}_{10}(5)$ ], below which the inoculum size  
96 is considered low at approximately  $\text{ID}_{50}$ ] and reached an objective study endpoint (urethral  
97 discharge or day 5). Six male participants were inoculated with wild type FA1090 A26 alone and  
98 included in downstream analyses. Of nine men inoculated with FA1090 $\Delta\text{mtrD}$  alone, two were  
99 excluded: one volunteer received a low inoculum dose at approximately  $\text{ID}_{50}$  [inoculum  
100 size= $\text{Log}_{10}(5.0)$ ] and a second volunteer requested treatment without signs, symptoms, or  
101 positive cultures on day 2 post inoculation. Among participants included in final analyses, there  
102 were no significant differences between the two strains with respect to infectivity, inoculum size,  
103 pyuria on treatment day, and time to treatment (Table 2). Among evaluable and infected  
104 volunteers, bacteriuria on treatment day did not differ significantly between the two strains  
105 (Table 2), nor were they deemed to be clinically meaningful. These results indicate the MtrCDE  
106 efflux pump is not required for urethral infection in experimentally infected men.

107

108

### 109 The MtrCDE efflux pump does not confer a fitness advantage during urethral infection of 110 men experimentally infected with strain FA1090 of *N. gonorrhoeae*

111 To determine whether the FA1090 Mtr efflux pump confers a fitness advantage to *N.*  
112 *gonorrhoeae* in the male urethra, we conducted competitive infections using mixed FA1090 and  
113 FA1090 $\Delta\text{mtrD}$  inocula. Twelve participants in four cohorts were inoculated with strain mixtures.  
114 The evaluable population for competitive index calculations included participants who received a  
115 dose of *N. gonorrhoeae* within 1  $\text{Log}_{10}$  of the intended dose ( $\text{Log}_{10} 6$ ) and reached an objective  
116 study endpoint (urethral discharge or day 5) for whom a competitive index (CI) could be  
117 calculated. Ten participants were evaluable and included in competitive fitness evaluations  
118 (Table 3). One volunteer was urine culture-negative on treatment day, and thus the CI could not  
119 be calculated. A second volunteer did not comply with specimen collection requirements,  
120 because of which the processed urines were not the first void of the day. Among evaluable  
121 participants, infectivity and course of infection parameters were similar to those in non-  
122 competitive infections (Table 3).

123

124 The proportion of each strain in the inoculum and in urine sediment collected from each  
125 participant on treatment day was determined by sub-culturing up to 96 colonies from each  
126 positive urine sediment culture and enumerating strain-specific colony-forming units (cfu) by  
127 real-time colony PCR (Supplementary Table 2). To assess whether the fitness of the  
128 FA1090 $\Delta\text{mtrD}$  mutant was different than that of wild type, the ratio of mutant cfu as identified  
129 by colony real-time PCR was compared to wild-type cfu for up to 96 recovered colonies per  
130 participant.  $\text{Log}_{10}(\text{CI})$  of participants inoculated with a mixture of FA1090 and FA1090 $\Delta\text{mtrD}$   
131 group were compared using a Wilcoxon one-sample signed rank test to a hypothetical median of  
132 0. We observed equal outcomes favoring the mutant strain and the wild type strain and overall  
133 there was not enough evidence to reject the null hypothesis ( $p = 0.477$ , one-sample signed rank  
134 test, Figure 1A). Thus, expression of the FA1090 Mtr efflux pump did not confer a competitive  
135 advantage during experimental human urethral infection.

136 **The *in vivo* fitness advantage of the Mtr efflux pump is strain dependent in female mice**

137 Given that previous studies on FA19 *mtr* mutant strains in female mice showed that *mtrD* and  
138 *mtrE* mutants were attenuated for murine vaginal infection, and that the Mtr pump is important  
139 for *in vivo* survival, either through induction by MtrA, the activator of the pump expression, or  
140 de-repression through loss of MtrR, the repressor of pump expression (8, 19, 24), the results of  
141 the human competitive infections with FA1090 and FA1090 $\Delta$ *mtrD* were unexpected.  
142 Furthermore, when investigating the role of LptA in FA1090 strains, which also increases  
143 gonococcal resistance to innate defenses such as cationic antimicrobial peptides, the two models  
144 showed similar results (29). Experimental infection of female BALB/c mice has been used  
145 extensively to study *N. gonorrhoeae* pathogenesis (8, 19, 24, 30-37). To determine whether this  
146 discrepancy reflected differences between model systems, between strains, or between mutant  
147 generation methodologies, we conducted competitive infections in female mice with the  
148 following strain mixtures of wild type and mutant: wild type FA1090 with FA1090 $\Delta$ *mtrD*, wild  
149 type FA19 with FA19 $\Delta$ *mtrD*, and wild type FA19 with FA19*mtrD*::*kan*, which was tested  
150 previously (19). For this study, groups of female BALB/c mice were vaginally inoculated with  
151 mixtures containing similar numbers of wild type and mutant bacteria (total dose, Log<sub>10</sub> 5.8-6).  
152 The number of colonies of each strain recovered from vaginal swabs was determined for up to  
153 5 days after inoculation; strain determination for each cfu was done by real-time PCR for  
154 competitive infections with FA1090 and FA1090 $\Delta$ *mtrD* and with FA19 and FA19 $\Delta$ *mtrD*;  
155 quantitative selective culture was used for FA19 and FA19*mtrD*::*kan* competitive infections.

156  
157 Among the 11 mice competitively infected with FA1090 and FA1090 $\Delta$ *mtrD* (Supplementary  
158 Table 3), we observed five outcomes that favored the wild type FA1090 and six outcomes that  
159 favored FA1090 $\Delta$ *mtrD* ( $p=0.672$  1-sided Fisher's exact, Figure 1B). There was no significant  
160 departure from the null hypothesis as the Log<sub>10</sub>(CIs) were not from different from the  
161 hypothetical median of 0 ( $p=0.943$ , Wilcoxon one-sample signed rank test). Results with  
162 FA1090 strains were not different in the two model systems ( $p=0.441$ , Mann-Whitney rank sum  
163 test), although more mice than men had mixed strain recovery on the final positive culture day  
164 (mice: 6 /11, 54.5%; men: 1/10, 10.0%,  $p=0.045$  one-sided Fisher's exact).

165  
166 Among the 7 mice infected with mixtures of FA19 and FA19 $\Delta$ *mtrD*, all but one outcome favored  
167 wild type FA19, with a significant difference from the hypothetical median of 0 ( $p=0.031$ ,  
168 Wilcoxon one-sample signed rank test, Figure 1B). The FA1090 and FA19 results were  
169 significantly different in the mouse model ( $p=0.047$ , Mann-Whitney rank sum test). All  
170 outcomes in the 6 mice competitively infected with FA19 and FA19*mtrD*::*kan* favored the wild  
171 type, with no mixed strain recovery on final day of positive cultures ( $p=0.030$ , Wilcoxon one-  
172 sample signed rank test, Figure 1C) in line with previously published results (8, 19, 24).

173  
174 We conclude that the *in vivo* phenotype of the FA1090 mutant that does not produce the MtrCDE  
175 pump is the same in the male urethritis and female mouse models, but that an interesting strain  
176 difference between FA1090 and FA19 mutants was detected in the mouse model.

177  
178 **Strain dynamics during human infection indicate the presence of a colonization bottleneck**

179 Lack of a functional Mtr efflux pump did not alter the fitness of the isogenic mutant relative to  
180 wild type FA1090. Thus, our strategy of competitive infection enabled the incidental observation  
181 of a potential urethral colonization bottleneck. Competitive infections with strains of equal

182 fitness have been used to study bottlenecks in other infection models. A bottleneck refers to  
183 barriers to colonization or infection that substantially reduce the original population size in an  
184 inoculum, such that a lower number of surviving organisms establish colonization and replicate  
185 in the host. Our findings indicate that such a bottleneck exists early in the course of gonococcal  
186 infection.

187  
188 Figure 2A depicts the theoretical outcomes of one individual infection initiated with a 50:50  
189 mixture of two hypothetical strains under conditions of bottleneck and absent bottleneck. When a  
190 bottleneck is not present, the strategy of competitive infections can have two outcomes: if both  
191 strains have equal fitness, the bacteria recovered from the host after inoculation mirrors the  
192 inoculum (outcome 1). If one of the strains has an advantage, the expectation is for that strain to  
193 progressively take over the dominate over the gonococcal population over course of infection  
194 (outcome 2). Under the scenario of a bottleneck, if the same strain is at a competitive advantage,  
195 then it is expected to dominate from early until late infection (outcome 3). When neither has a  
196 fitness advantage and a bottleneck is preset, both strains will have equal chance of passing  
197 through the bottleneck and establishing an infection; therefore, in outcome 4, equal numbers of  
198 competitive infections would be dominated by each strain.

199  
200 Figure 2B describes the observed outcomes for urine culture positive days in each of the 10  
201 evaluable human participants, who on average received 40:60 mixed inocula of FA1090 and  
202 FA1090 $\Delta$ *mtrD*. In the majority of men (8/10, 80.0%, Figure 2B), the predominant FA1090 strain  
203 on treatment day began dominating early in the infection (day 1 post-inoculation). In 2/10 men  
204 (20.0%), the predominating FA1090 strain from treatment day was different than the strain  
205 dominating the recovered *N. gonorrhoeae* cfu from day 1 post-inoculation. In all but one man  
206 (9/10, 90.0%), the strain composition of the first void urine on the final study day was uniformly  
207 dominated by either strain. Strain dynamics from urine culture positive days support the  
208 gonococcal bottleneck hypothesis.

209  
210



## 211 Discussion

212  
213 In the female mouse model of gonorrhoea, the MtrCDE efflux pump was found to be important to  
214 *in vivo* infection with *N. gonorrhoeae* strain FA19 (8, 19, 24). We anticipated human competitive  
215 infections with wild type FA1090 and an isogenic polar mutant of FA1090 that lacked a  
216 functional MtrCDE efflux pump to yield similar results. Contrary to our hypothesis, the two  
217 strains exhibited equal fitness. The previous investigations using the murine model were  
218 conducted with wild type strain FA19 and FA19 mutants whose MtrCDE efflux pump was  
219 rendered non-functional via insertional inactivation (8, 19, 24). Thus, the discrepancy between  
220 human and mouse results could be a reflection of strain, model, or mutagenesis methodology  
221 differences. To separate potential differences with respect to strain, we conducted competitive  
222 infections in mice with both FA1090 and FA19 parent strains and corresponding mutants that  
223 lacked a functional MtrCDE efflux pump due to clean deletions of the *mtrD* gene  
224 (FA1090 $\Delta$ *mtrD* and FA19 $\Delta$ *mtrD*). The FA1090 strains used in mouse infections were the same  
225 strains used in human infections. The outcomes of competitive infection with FA1090 strains did  
226 not differ between two model systems, indicating that the Mtr pump is not required for  
227 colonization of murine lower genital tracts or human male urethras. However, mouse competitive  
228 infections with FA19 strains showed that FA19 wild type had significant competitive advantage  
229 relative to FA19 $\Delta$ *mtrD*. This competitive advantage was maintained when tested against the  
230 same insertional inactivated *mtrD* mutant used in the previous report (19). Nevertheless,  
231 differences between infection models and mutagenesis strategies were noted, namely the more  
232 frequent recovery of both wild type and mutant strains from mice compared to men during  
233 competitive infections with FA10190 strains, and from mice inoculated with wild type FA19 in  
234 combination with FA19 $\Delta$ *mtrD* relative to mice inoculated with wild type FA19 and  
235 FA19*mtrD*::kan. Overall, our findings indicate that the fitness advantage conferred by the  
236 MtrCDE efflux pump in the murine infection model is strain-dependent. Two established lines  
237 of evidence suggest that strain dependent differences in MtrCDE-mediated enhanced fitness may  
238 also be present during human infection. First, FA1090 naturally expresses reduced levels of the  
239 pump compared to other strains, including FA19, due to an 11 bp deletion in the coding region  
240 of *mtrA* that results in loss of MtrA-mediated gene activation due to premature truncation of this  
241 transcriptional activator (18, 23). Thus, the null mutation in the *mtrD* gene in FA1090 may not  
242 result in a strong fitness phenotype compared to the parental FA1090 strain that already  
243 expresses a low level of MtrCDE (*i.e.*, low expression in the wild type *vs.* no expression in the  
244 mutant). This is consistent with the observed equal fitness of the strains during human and mouse  
245 competitive infections. Second, a recent compelling study that investigated the population  
246 genomics of the *mtrCDE* operon and its regulatory genes *mtrA* and *mtrR* using almost 5,000  
247 global *N. gonorrhoeae* genomes, found that loss-of-function mutations related to the expression  
248 of the MtrCDE efflux pump are relatively common in nature (38). In this global meta-analysis  
249 (38), 362/4842 isolates (7.48%) were found to not have an inducible MtrCDE efflux pump due to  
250 mutations in *mtrA*, of which the vast majority (357/362, 98.6%) harbored the same 11-bp  
251 deletion as FA1090 *mtrA*. FA1090 was originally isolated from the endocervix of a female with  
252 probable disseminated gonococcal infection (39) and the global population genomics study  
253 found that loss of function mutations were over-represented among genomes from cervical  
254 isolates; 25 of 129 cervical isolates (19.4%) carried *mtrA* loss of function mutations compared to  
255 61 out of 2,248 urethral isolates (2.71%) (38). This finding indicates that strains with low levels  
256 of MtrCDE efflux pump expression colonize the genital tracts of both females and males. Thus,

257 it may be reasonable to conclude that the possibility of strain-dependent requirement of the  
258 MtrCDE efflux pump is representative of other naturally occurring gonococcal strains with non-  
259 inducible MtrCDE efflux pumps. Although the pump may not be required to establish infection  
260 in humans, evolving evidence suggests that overproducers of the pump may be better positioned  
261 for antimicrobial resistance, as position 823 in MtrD is predicted to be a site for binding  
262 antimicrobials (38, 40).

263  
264 The equal fitness of FA1090 and FA1090 $\Delta$ *mtrD* in urethral infection observed using competitive  
265 infection enabled the identification of a within-host bottleneck during the gonococcal infection  
266 process. To our knowledge, this is the first demonstration that productive infection with *N.*  
267 *gonorrhoeae* is likely initiated by a restricted number of gonococci rather than through a uniform  
268 expansion of the initial mixed inoculum, though the concept of a gonococcal colonization  
269 bottleneck was previously proposed (27). Transmission or colonization bottlenecks are drastic  
270 reductions in population size followed by clonal expansion of the “founder” organisms that  
271 initiate the productive infection. Bottlenecks have been observed in enteric and systemic  
272 infections caused by pathogenic bacteria in humans (41-47). Among sexually-transmitted  
273 infections, human immunodeficiency virus 1 (HIV-1) bottlenecks have been studied but to date  
274 no studies have demonstrated their presence in bacterial sexually transmitted infections (48-51).

275  
276 We tracked the daily strain dynamics during human competitive infections from day 1 post-  
277 inoculation until the day of clinical urethritis (Figure 2). We noted that the “winning” strain  
278 outcompeted the “losing” strain within the first 24h of inoculation in the majority of participants  
279 (8/10) and persisted as dominant strain until the final study day. However, both strains were  
280 recovered from 8/29 positive cultures of 4/10 volunteers, albeit at very different proportions.  
281 Interestingly, in 2 participants (302 and 313) in which both strains were recovered, the strain  
282 dominance observed on the first day after inoculation reversed the following day. While the  
283 study was not designed *a priori* to study population bottlenecks during *in vivo N. gonorrhoeae*  
284 infection, our findings allude to some possible bottleneck characteristics with respect to type  
285 (selective or non-selective), size (how many organisms are able to breach the initial barrier?),  
286 and timing.

287  
288 First, it is possible that the gonococcal bottleneck is non-selective and strains overcome the  
289 bottleneck with equal probability, as observed in murine models of *Streptococcus pneumoniae*  
290 infection (43, 53-56). Our imposed genetic diversity of two strains is insufficient to answer this  
291 question with any certainty. A selective bottleneck has also been described using *in vitro*  
292 selection with human serum and in baby rat models of infection with the only other pathogenic  
293 neisserial species, *Neisseria meningitidis* which happens to share 80-90% of its genome with the  
294 gonococcus (61). The study showed experimentally that even when controlling for inoculum size  
295 a strongly selective bottleneck for survival of meningococci is generated by bactericidal antibody  
296 directed against the carbohydrate antigen produced by the phase variable enzyme LOS  
297 glycosyltransferase G, *lgtG* (61). Meningococcal variants existing within a population that do not  
298 express *lgtG* survive when exposed to a bactericidal monoclonal antibody specific for the  
299 epitope, whereas isogenic “ON” variants are killed essentially selecting for minority *lgtG* “OFF”  
300 variants. Similar dynamics were observed in an infant rat model given the monoclonal antibody,  
301 with *lgtG* “OFF” variants escaping into the bloodstream after intraperitoneal inoculation.  
302 Interestingly, the same gene also exists in *N. gonorrhoeae* (LOS glycosyltransferase G, *lgtG*)



303 (62) and it too undergoes phase variation (63) and is the target of a monoclonal antibody with  
304 promising immunotherapeutic potential (64, 65).

305  
306 While the exact gonococcal bottleneck size cannot be inferred from our data, the recovery of  
307 both strains from the same urine specimen indicates that the bottleneck is wider than one single  
308 cell. This would stand in contrast to bottlenecks for other human bacterial pathogens, which have  
309 tight single-cell bottlenecks (43, 45, 66) or for HIV-1 in which 80% of HIV-1 heterosexual  
310 transmission is initiated from a single HIV-1 genetic variant (48-51), reviewed in (47).

311  
312 Finally, based on the data in the current study, the timing of the bottleneck may vary between  
313 individuals and/or there may be more than one sequential bottleneck in play over the first 48  
314 hours after exposure to *N. gonorrhoeae*. The timing of urine sampling in our experiments (every  
315 24h) is likely too infrequent to precisely determine the timing of the bottleneck. However,  
316 previous studies on the kinetics of opacity protein selection and pilin antigenic variation during  
317 experimental human infection with FA1090 support the idea that the infecting population  
318 encounters strong selective forces early in the infection process (67-70). Opacity and pilin  
319 proteins are known for their extensive phase and antigenic variation in *N. gonorrhoeae*. The  
320 opacity and pilin protein repertoire relative to the inoculum among the gonococcal isolates  
321 recovered from experimentally infected males (67-70) undergoes rapid shifts and becomes  
322 progressively more complex as infection progresses (67-70), consistent with the idea that  
323 gonococci breaching the initial barrier may encounter additional pressures (e.g., host immune  
324 responses). The phenomenon of increased phase variation as a strategy to overcome bottlenecks  
325 and regenerate population diversity has been previously described for other bacteria (71-75).  
326 Whole genome and transcriptome studies utilizing the daily gonococcal samples from the  
327 experimentally infected males of the current study to investigate phase variation and  
328 transcriptomic dynamics are an important extension of this reported study that are currently  
329 being undertaken.

330  
331 In addition to the inherent limitations in characterizing the gonococcal bottleneck described  
332 above, open questions also remain with respect to the *in vivo* requirement of the MtrCDE efflux  
333 pump in human urethral infection. FA19 strains have not been characterized as a human  
334 challenge strain, and thus human experimental infection with FA19 strains were not possible to  
335 formally evaluate that the requirement of the MtrCDE pump is strain dependent in the human  
336 male urethra. It is possible that the MtrCDE pump simply does not provide an advantage in the  
337 male urethra, but confers a selective advantage in other ecologic niches, like the mouse vagina  
338 and possibly some anatomic sites in humans. By culturing urine rather than specimens directly  
339 sampled from the urethral mucosa, it is possible that the adherent infecting bacterial population  
340 is different from the bacteria that are shed and carried out of the urethra by flowing urine.  
341 Finally, whether the data of the experimental infections in males is representative of female  
342 infection or of extragenital sites remains an open question. Due to the risk of ascending  
343 gonococcal infection, experimental gonorrhea in females is not ethically acceptable. Controlled  
344 human infection models of the oropharynx and rectum do not exist yet.

345  
346 Overall, our study has provided compelling information regarding the MtrCDE efflux pump, a  
347 well-studied *N. gonorrhoeae* virulence factor, and the presence of a population restriction  
348 bottleneck during *in vivo* human infection. By showing that a strain of *N. gonorrhoeae* is able to

349 initiate a productive infection in the human male urethra even when the pump is not functional  
350 we have generated data that can inform future gonorrhea vaccine and drug development efforts  
351 that target the function of the Mtr efflux pump. By showing for the first time for a bacterial  
352 sexually-transmitted pathogen that a bottleneck exists during *in vivo* human urethral infection we  
353 have pointed towards a gonococcal Achilles heel could be exploited for novel control strategies;  
354 knowledge of which host pressures drive the restriction of the pathogen population may answer  
355 important biological questions regarding gonococcal infection progression or reveal genes that  
356 are essential to the survival of *N. gonorrhoeae*. For example, as many as a third of all exposed  
357 individuals will not develop an infection and of the 66% of exposures that proceed to infection,  
358 ~50% of female genital infections and ~20% of male genital infection remain asymptomatic  
359 (data reviewed in (52)). The determinants of these phenomena are unknown and physiologic  
360 bottlenecks could play a role. Thus, the implications of our findings could have the potential of  
361 ushering in fresh lines of inquiry in our quest for new and effective anti-gonococcal strategies.  
362 This is important because in the face of increasing gonorrhea incidence and *N. gonorrhoeae*'s  
363 superbug status, the need to contain the threat of untreatable gonorrhea has become paramount.  
364

## 365 **Methods**

### 366 **Strains**

367 *N. gonorrhoeae* strains used in this study are listed in Table 1. *N. gonorrhoeae* FA1090 served as  
368 the parent strain for the human challenge investigations, whereas wild type FA1090 and FA19  
369 were the parent strains for the mouse challenge experiments. FA1090 is a porin serotype PIB-3,  
370 streptomycin (Sm)-resistant strain that has been used extensively in experimental human  
371 infection studies (27). FA19 has been used widely in mouse challenge studies, including studies  
372 of the Mtr efflux pump. The FA1090 human challenge inoculum strain, including the FA1090  
373 A26 variant utilized in the current studies in men and mice is piliated and predominantly Opa-  
374 negative. FA1090 $\Delta$ *mtrD* is an isogenic mutant of FA1090, generated according to procedures  
375 described below. In addition to FA1090 A26 and FA1090 $\Delta$ *mtrD*, three other FA19 strains were  
376 used in mouse challenge experiments (FA19 wild type and two mutant strains lacking a  
377 functional Mtr pump, namely FA19 $\Delta$ *mtrD*, and FA19 *mtrD*::*kan*).  
378  
379

### 380 **Generation and characterization of the mutant strains**

381 To delete the *mtrD* gene and generate FA1090 $\Delta$ *mtrD*, a single colony of the FA1090 A26 as the  
382 starting material was used in a two-step transformation, as previously described (81) and used by  
383 us to delete *lptA* in FA1090. The deletion was made without leaving behind a selectable marker  
384 (Supplementary Figure 1). Briefly, a two-gene cassette containing both a selectable marker  
385 (chloramphenicol acetyl transferase [CAT] conferring chloramphenicol [Cm] resistance) and a  
386 counter selectable marker (*rpsL*, conferring streptomycin [Sm] susceptibility on the naturally  
387 resistant FA1090) was cloned into the *mtrD* gene and used to replace the wild type gene on the  
388 chromosome by allelic exchange. A second transformation replaced the cassette-containing  
389 version of the gene with an unmarked deletion. Targeted PCR amplification of the *mtrD* locus  
390 and whole-genome sequencing of the FA1090 $\Delta$ *mtrD* genome sequence confirmed deletion of the  
391 gene in the mutant. FA19 $\Delta$ *mtrD* was generated in the same manner as FA1090 $\Delta$ *mtrD* (i.e.,  
392 leaving behind a clean deletion without a selectable marker), whereas the FA19 *mtrD*::*kan*  
393 mutant was constructed via an insertional mutation, leaving behind a kanamycin selectable  
394 marker, as previously described (19). While the mutant strains express the other two components

395 of the Mtr efflux pump, the lack of *mtrD* expression leads to the inability to assemble the pump.  
396 MtrD expression contributes to gonococcal resistance to cationic antimicrobial compounds such  
397 as polymyxin B (PB). Compared to parental strain FA1090 A26 the *mtrD* deletion mutant was  
398 four-fold more PB susceptible (MICs of 100 vs. 25 µg/ml, respectively).  
399

400

### 401 **Human urethral experimental infections**

402 Procedures for human male participant recruitment, informed consent, intraurethral inoculation,  
403 an antibiotic treatment were as previously described (27, 28, 82, 83). Females are excluded from  
404 these studies due to risks of ascending gonorrhea infection into the upper reproductive tract.  
405 Between April 2017 and November 2018, separate cohorts of up to 4 participants were  
406 inoculated with FA1090 A26 alone, FA1090Δ*mtrD* alone, or with mixtures of FA1090 A26  
407 combined with FA1090Δ*mtrD* containing approximately one million organisms. Gonococci in  
408 the inoculum suspensions were predominantly Opa-negative, piliated and expressed the same  
409 Pile sequence as previously characterized FA1090 variants used in experimental human  
410 infection studies(29, 68). For competitive infections in men, mixtures of wild type FA1090 A26  
411 and FA1090Δ*mtrD* were prepared ahead of time and stored at -≤70°C until use. Procedures  
412 pertaining to inoculum preparation for single and mixed strain infections have been previously  
413 described (27-30, 82).  
414

414

415 Participants were observed for up to 5 days post-inoculation and received antibiotics as soon as  
416 discharge developed or on the final day of study (day 5 post-inoculation, irrespective of whether  
417 they were deemed to be infected or not). Antibiotic treatment was with cefixime (single 400 mg  
418 oral dose) or ceftriaxone (single 250 mg dose delivered intramuscularly). Infection alone without  
419 discharge did not trigger treatment. First-void urine specimens were obtained daily after  
420 inoculation for up to five days and examined quantitatively for pyuria (white blood cells) and  
421 gonococci (bacteriuria). Participants were considered to be infected if they had a positive urine  
422 culture or positive swab culture, with or without symptoms (i.e., urethral discharge). Urine  
423 sediment was cultured quantitatively on GC agar with 3 g vancomycin, 12.5 units nystatin, and 5  
424 g trimethoprim lactate/ml, which permits the growth of FA1090 and FA1090Δ*mtrD*. Inocula  
425 used in single and mixed strain human challenges were also plated quantitatively. Colonies were  
426 enumerated for bacterial quantitation. Up to 96 colonies per volunteer per culture day and up to  
427 96 colonies from mixed inocula were picked and stored in freezing medium until strain  
428 determination by real-time PCR.  
429

429

### 430 **Murine competitive infections**

431 Female BALB/c mice (6 to 8 weeks old) were treated with Premarin and antibiotics to increase  
432 susceptibility to *N. gonorrhoeae* as described previously (19, 84). Mixtures of relevant strains  
433 were prepared on challenge day, as previously described (19). Groups of mice were inoculated  
434 vaginally with the following mixtures: FA1090 and FA1090Δ*mtrD*, FA19 and FA19Δ*mtrD*, or  
435 FA19 and FA19 *mtrD*:*kan*. Vaginal swabs were collected every other day for 5 days starting on  
436 day 1 post-inoculation and suspended in 100 µl GC broth. For mixtures containing deletion  
437 mutants, vaginal swab suspensions were quantitatively cultured for *N. gonorrhoeae* on GCB  
438 plates with Sm (100 µg /ml) plus 10 µg PMB/ml. Up to 48 colonies per mouse per culture day  
439 were picked and stored in freezing medium until shipment to UNC-CH for strain determination  
440 by real-time PCR, as described below. For competitive infections with FA19 and

441 FA19 *mtrD::kan*, vaginal swab suspensions were cultured on GC agar with Sm (100 µg /ml) for  
442 total CFU counts (wild-type and mutant) and GC agar with Sm (100 µg /ml) plus Km (50 µg/ml)  
443 to determine mutant CFU counts.

444  
445

#### 446 **Strain determination in human competitive infections that contained clean deletion** 447 **mutants**

448 Up to 96 colonies per human male volunteer per culture day and up to 48 colonies per mouse per  
449 culture day were individually tested for strain determination using a duplex Taqman real-time  
450 PCR assay (Supplementary Figure 1). Frozen, viable material from each colony was sub-cultured  
451 in sterile 96 well microtiter plates by adding gonococci to 75 µL of sterile GC broth (with  
452 supplements) using aseptic technique and a replica plater tool. Gonococci were expanded  
453 overnight (18-24h) at 35-37°C in a humidified atmosphere containing 5-7% CO<sub>2</sub> in order to  
454 generate enough bacterial material for DNA isolation and subsequent strain detection by real  
455 time PCR.

456

457 Bacterial lysates were generated according to established procedures (85). Resulting lysates were  
458 used as DNA template in the real-time assay. In brief, each well containing bacterial material  
459 expanded from a single colony was placed in 75 µL of sterile lysis buffer containing 2 mM  
460 EDTA, 50 mM Tris Cl at pH 8.5, and 1% Triton X-100 (85). Cells were lysed in 96-well PCR  
461 plates using a thermocycler under the following cycling conditions: 15 min at 94°C followed by  
462 incubation for 5 min at 25°C. Control lysates from each individual strain were made and  
463 included as controls on each assay plate.

464

465 The simultaneous and specific detection of wild type and mutant strains was possible for three  
466 reasons (Supplementary Figure 1): 1) the wild type specific primers and probe were located  
467 within the *mtrD* gene, which is deleted in the mutant strains, and produce a 164bp product (note:  
468 the *mtrD* gene in FA1090 and FA19 have 100% genetic homology); 2) the primers and probe  
469 targeting the mutant strain were designed in a gap PCR fashion, whereby the forward and reverse  
470 primers flank the *mtrD* deletion and the probe spans either side of the deletion; only if a deletion  
471 is present, can the real-time assay utilize these primers and probe to amplify and detect the HEX-  
472 labeled 221 bp product; and 3) the two probes were labeled with two different fluorophores with  
473 non-overlapping emission spectra (wild type probe was labeled at the 5' end with the FAM  
474 fluorophore, which has an emission spectrum of 510-530 nm; and mutant probe was labeled at  
475 the 5' end with HEX fluorophore, which has an emission spectrum of 560-580 nm). Real-time  
476 assays were run in 384 well plates with five positive and five negative controls on each plate  
477 using a ViiA 7 Real-Time PCR System from Applied Biosystems and the following cycling  
478 conditions: 1 cycle at 95°C for 3 min, followed by 40 cycles at each of 95°C for 15 sec and 58°C  
479 for 45 seconds. Primer and probe sequences, and PCR recipes are provided in Supplementary  
480 Table 3. Only wells which gave a positive amplification signal for one, but not both targets, were  
481 included for enumeration and competitive index calculation.

482

483

#### 484 **Competitive index calculations**

485 For experimental murine and human infections, results for infected individuals were expressed as  
486 a competitive index (CI) using the equation:

487

$$CI = \frac{\text{mutant CFU (output)} / \text{wild-type CFU (output)}}{\text{mutant CFU (input)} / \text{wild-type CFU (input)}}$$

488 Where

489 Output refers to the number of wild type and mutant cfu enumerated from cultures of urine  
490 sediment or from cultures of mouse vaginal swab suspension

491 Input refers to the number of cfu enumerated from culture of bacterial suspension used to  
492 inoculate that particular cohort/group of men or mice.

493

494 For human and mouse competitive infections, the culture limit of detection was assigned as 1  
495 cfu/output cfu (e.g., 1/96 or 1/48, respectively). The competitive index can be equal to 1 if there  
496 is equal fitness between the two strain, greater than 1 (or greater than 0 when expressed on the  
497 logarithmic scale) if the mutant is favored or less than 1 (or less than 0 when expressed on the  
498 logarithmic scale) if the wild type is favored.

499

### 500 **Statistics**

501 The evaluable population in non-competitive infections included participants who received a  
502 dose of *N. gonorrhoeae* within 1 Log<sub>10</sub> of the intended dose and reached an objective study  
503 endpoint (urethral discharge or day 5). The evaluable population in competitive infections  
504 included participants who received a dose of *N. gonorrhoeae* within 1 Log<sub>10</sub> of the intended  
505 dose, reached an objective study endpoint (urethral discharge or day 5) and had at least one  
506 positive urine culture.

507

508 Differences between groups were evaluated by Mann-Whitney rank-sum tests, 1-sided Fisher  
509 exact tests, or Kruskal-Wallis test, as appropriate. The CI of the mixed group was tested against  
510 the null hypothesis that the median equal zero using the one-sample Wilcoxon sign rank test and  
511 alpha of 0.05.

512

### 513 **Study approvals**

514 Written informed consent from each participant was obtained prior to conducting any study  
515 activities. Experimental human infections were conducted between 2017-2019 in the Clinical and  
516 Translational Research Center of the North Carolina Translational and Clinical Sciences Institute  
517 at the University of North Carolina at Chapel Hill according to the guidelines of the U.S.  
518 Department of Health and Human Services and the University's Institutional Review Board  
519 under a protocol for use of an investigational new drug (IND) that was authorized by the U.S.  
520 Food and Drug Administration.

521 All animal experiments were conducted at the Uniformed Services University of the Health  
522 Sciences according to the guidelines of the Association for the Assessment and Accreditation of  
523 Laboratory Animal Care under a protocol that was approved by the University's Institutional  
524 Animal Care and Use Committee.

### 525 **Author contributions**

526



527 MMH and JAD designed the research study, revised the manuscript, and conducted the human  
528 experimental infections in conjunction with the UNC-Global Clinical Trials Unit/DMID 09-0106  
529 Study Team. AW performed microbiology assessments and drafted the manuscript. MMH and  
530 AW conducted data analysis. NH performed statistical analysis. WMS and JTB generated the  
531 mutant strains. AEJ, KLC, and AAB conducted all the animal challenge studies. WMS and AEJ  
532 edited the manuscript.

533  
534

### 535 **Acknowledgments and Funding Information**

536

537 We extend our gratitude to the study participants. James Anderson and Lorraine Ballea provided  
538 technical support for the microbiologic assessments. See Supplemental Acknowledgments for  
539 UNC-Global Clinical Trials Unit/DMID 09-0106 Study Team member details. We are grateful to  
540 Holly Baughman and Jill El-Khorazaty from Emmes for the input on the study. The authors and  
541 study were supported by funding from the National Institutes of Health, National Center for  
542 Advancing Translational Sciences, National Institute of Allergy and Infectious Diseases, and  
543 National Institute of General Medical Sciences through Grant Award Numbers U01AI114378,  
544 TL1TR002491, UL1TR001111, R01AI021150 and U19AI113170. W.M.S. is the recipient of a  
545 Senior Research Career Scientist Award from the Department of Veterans Affairs Medical  
546 Research Service.

547  
548  
549

550 **Main Figures and Tables**

551

552

553 **Table 1. Bacterial strains used in this study**

554

| <b>Strain</b>               | <b>MtrD pump expression</b>   | <b>Reference</b>    |
|-----------------------------|---|---------------------|
| FA1090 A26                  | Not inducible due to 11 bp deletion in coding region of activator <i>mtrA</i> | (39)                |
| FA1090 $\Delta$ <i>mtrD</i> | None  | This study          |
| FA19                        | Inducible (wild type <i>mtrA</i> )  | (86)                |
| FA19 $\Delta$ <i>mtrD</i>   | None  | This study          |
| FA19 <i>mtrD::kan</i>       | None  | This study and (19) |

555

556

557

558 **Table 2. Clinical course parameters of non-competitive infections in men inoculated with *N.***  
 559 ***gonorrhoeae* FA1090 or *N. gonorrhoeae* FA1090Δ*mtrD***  
 560

| Participant                       | Strain                 | Inoculum size <sup>a</sup> | Infected?               | Bacteriuria <sup>b</sup> | Pyuria <sup>c</sup>  | Day of Treatment <sup>d</sup> |
|-----------------------------------|------------------------|----------------------------|-------------------------|--------------------------|----------------------|-------------------------------|
| 232                               | FA1090                 | 6.6                        | Y                       | 6.4                      | 6.7                  | 3                             |
| 241                               |                        | 6.8                        | Y                       | 4.5                      | 6.3                  | 2                             |
| 242                               |                        | 6.7                        | Y                       | 6.3                      | 7.0                  | 3                             |
| 243                               |                        | 6.8                        | Y                       | 5.5                      | 7.1                  | 3                             |
| 251                               |                        | 5.9                        | Y                       | 2.0                      | 6.4                  | 1                             |
| 252                               |                        | 6                          | Y                       | 6.0                      | 6.9                  | 4                             |
| <b>Summary<sup>e</sup></b>        |                        | <b>6.5 (6.0-6.9)</b>       | <b>100% (54%, 100%)</b> | <b>4.8 (3.0-7.6)</b>     | <b>6.7 (6.4-7.1)</b> | <b>3.0 (2-3)</b>              |
| 216                               | FA1090Δ<br><i>mtrD</i> | 5.8                        | Y                       | 6.2                      | 6.2                  | 3                             |
| 220                               |                        | 6.4                        | Y                       | 3.2                      | 6.8                  | 1                             |
| 222                               |                        | 6.7                        | Y                       | 4.0                      | 8.0                  | 2                             |
| 223                               |                        | 6.7                        | Y                       | 6.0                      | 8.0                  | 3                             |
| 271                               |                        | 6.0                        | Y                       | 0.7                      | 6.0                  | 4                             |
| 272                               |                        | 6.1                        | N                       | ND                       | 6.0                  | 5                             |
| 273                               |                        | 6.1                        | Y                       | 2.0                      | 6.9                  | 4                             |
| <b>Summary<sup>e</sup></b>        |                        | <b>6.2 (5.9-6.6)</b>       | <b>86% (42%, 100%)</b>  | <b>3.0 (1.2-7.0)</b>     | <b>6.8 (6.1-7.6)</b> | <b>3.0 (2-4)</b>              |
| <b><i>p-value</i><sup>g</sup></b> |                        | <b>0.39</b>                | <b>0.54</b>             | <b>0.23</b>              | <b>0.77</b>          | <b>0.50</b>                   |

561 Y=yes, N=no

562 <sup>a</sup>Log<sub>10</sub> CFU *N. gonorrhoeae* mixture delivered to intraurethrally

563 <sup>b</sup>Log<sub>10</sub> CFU *N. gonorrhoeae* recovered/mL urine sediment on day of treatment

564 <sup>c</sup>Log<sub>10</sub> wbc/mL urine sediment on day of treatment

565 <sup>d</sup>Days from inoculation to antibiotic <sup>e</sup>Summary statistics refer to geometric means with 95%  
 566 confidence intervals shown in brackets, except for the infectivity summary, which denotes the  
 567 percentage of participants deemed to have been infected (with 95% confidence intervals), and  
 568 time to treatment, which denotes the median time from inoculation to treatment (with  
 569 interquartile range). P-values were generated using the two-sided two-sample Wilcoxon rank-  
 570 sum test, except for the infectivity comparison for which the one-sided Fisher's exact test was  
 571 used.

572

573

574

575 **Table 3. Infectivity and course of infection parameters in men infected competitively with**  
 576 **FA1090+FA1090Δ*mtrD*, and comparisons to the same parameters from non-competitive**  
 577 **infections in men.**

578

| Participant                       | Strain                 | Inoculum size <sup>a</sup> | Infected?               | Bacteriuria <sup>b</sup> | Pyuria <sup>c</sup>  | Day of Treatment <sup>d</sup> |
|-----------------------------------|------------------------|----------------------------|-------------------------|--------------------------|----------------------|-------------------------------|
| 281                               |                        | 6.6                        | Y                       | 2.9                      | 7.1                  | 2                             |
| 291                               |                        | 5.8                        | Y                       | 5.2                      | 6.9                  | 4                             |
| 292                               |                        | 5.8                        | Y                       | 5.0                      | 6.5                  | 4                             |
| 300                               |                        | 6.5                        | Y                       | 4.6                      | 6.9                  | 4                             |
| 301                               | FA1090+                | 6.5                        | Y                       | 5.1                      | 6.5                  | 3                             |
| 302                               | FA1090Δ                | 6.6                        | Y                       | 5.0                      | 6.3                  | 2                             |
| 303                               | <i>mtrD</i>            | 6.5                        | Y                       | 5.0                      | 6.6                  | 4                             |
| 311                               |                        | 6.5                        | Y                       | 3.2                      | 6.9                  | 2                             |
| 313                               |                        | 6.3                        | Y                       | 3.5                      | 6.8                  | 4                             |
| 314                               |                        | 6.4                        | Y                       | 3.5                      | 7.0                  | 4                             |
| <b>Summary<sup>e</sup></b>        |                        | <b>6.3 (6.1-6.6)</b>       | <b>100% (69%, 100%)</b> | <b>4.2 (3.6-4.9)</b>     | <b>6.7 (6.6-6.9)</b> | <b>4 (2.0-4.0)</b>            |
| <b>Summary</b>                    | FA1090                 | <b>6.5 (6.0-6.9)</b>       | <b>100% (54%, 100%)</b> | <b>4.8 (3.0-7.6)</b>     | <b>6.7 (6.4-7.1)</b> | <b>3.0 (2.0-3.0)</b>          |
| <b>Summary</b>                    | FA1090Δ<br><i>mtrD</i> | <b>6.2 (5.9-6.6)</b>       | <b>86% (42%, 100%)</b>  | <b>3.0 (1.2-7.0)</b>     | <b>6.8 (6.1-7.6)</b> | <b>3.0 (2.0-4.0)</b>          |
| <b><i>p-value<sup>f</sup></i></b> |                        | <b>0.38</b>                | <b>0.56</b>             | <b>0.25</b>              | <b>0.91</b>          | <b>0.48</b>                   |

579 Y=yes, N=no

580 <sup>a</sup>Log<sub>10</sub> CFU *N. gonorrhoeae* mixture delivered intraurethraly

581 <sup>b</sup>Log<sub>10</sub> CFU *N. gonorrhoeae* recovered/mL urine sediment on day of treatment

582 <sup>c</sup>Log<sub>10</sub> wbc/mL urine sediment on day of treatment


583 <sup>d</sup>Days from inoculation to antibiotic treatment

584 <sup>e</sup>Summary statistics refer to geometric means with 95% confidence intervals shown in brackets,  
 585 except for the infectivity summary, which denotes the percentage of participants deemed to have  
 586 been infected (with 95% confidence intervals) and time to treatment, which denotes median time  
 587 from inoculation to treatment (with interquartile range). P-values were generated using Kruskal-  
 588 Wallis tests, except for the infectivity comparison for which the Fisher's exact test was used.

589

590

591




592  
593

**Figure 1. Results of competitive infections in men (n=10) and female mice.**

- 594 **A.** Ten men were competitively infected with mixtures of FA1090 and FA1090ΔmtrD.  
 595 Competitive indices were calculated as  $\text{cfu mut OUT}/\text{cfu wt OUT} \div \text{cfu mut IN}/\text{cfu wt IN}$  recovered from first-void urine of experimentally infected men. CIs are graphed on  
 596 the logarithmic scale. Thus,  $\text{Log}_{10}\text{CI}$  greater than 0 indicated the mutant was favored and  
 597  $\text{Log}_{10}\text{CI}$  less than 0 indicates that the wild type was favored. For men, the last day of  
 598 positive cultures was treatment day when clinical urethritis was detected and/or when  
 599 antibiotic treatment was given. Horizontal bars are the median CI for each group. White  
 600 squares refer to men from whom only the wild type was recovered the day of treatment.  
 601 Grey squares denote men from whom a mix of the two strains was recovered. Black  
 602 squares denote men from whom only the mutant strain was recovered.
- 603 **B.** Eleven mice were inoculated with mixtures of FA1090 and FA1090ΔmtrD and 7 mice  
 604 with mixtures of FA19 and FA19ΔmtrD. CIs were calculated using the same formula as  
 605 for the men using the cfu counts from mouse vaginal swabs on the last day of positive  
 606 cultures. CIs are graphed on the logarithmic scale. Horizontal bars are the median CI for  
 607 each group. White squares refer to mice from whom only the wild type was recovered on  
 608 last day of positive cultures. Grey squares denote mice from whom a mix of the two  
 609  
 610



611 strains was recovered. Black squares denote mice from whom only the mutant strain was  
612 recovered.  
613 C. Six mice were inoculated with mixtures of FA19 and FA19*mtrD::kan* and CIs calculated  
614 using cfu counts from mouse vaginal swabs on the last day of positive cultures. CIs are  
615 graphed on the logarithmic scale. Note the different y axis scale for panel C, imposed by  
616 the lower limit of detection of quantitative selective culture on GC agar for the  
617 FA19+FA19 *mtrD::kan* competitive infections.



618  
619  
620

621 **Figure 2. Gonococcal population dynamics during the early course of infection.**

622 A) Theoretical infection outcomes with respect to strain composition for infections initiated from  
623 50:50 mixtures of two strains, shown in black and white, that differ in their competitive  
624 advantage in scenarios of bottleneck present early in the infection or no bottleneck (adapted with  
625 permission from (27)). Each pie chart represents a gonococcal population containing predicted  
626 proportions of the two theoretical strains. When the two strains have equal fitness and a  
627 bottleneck is present early in the course of infection that results in a population size restriction,  
628 we predict that equal numbers of outcomes favoring each strain will be observed.

629 B) Empirically observed outcomes in the current study for infections initiated with mixed  
630 inocula. Two to four men were inoculated with the same inoculum preparation in each of the  
631 four study cohorts. A total of 10 evaluable participants were available for final analysis (281,  
632 291, 292, 300, 301, 302, 303, 311, 313, 314). The pie chart representing the average inoculum  
633 from the four cohorts refers to the mean strain composition of the four independent inocula and  
634 on average comprised of 60% mutant strain and 40% wild type. Each participant pie chart

635 represents the daily mixture of gonococcal strains recovered from the urine over the 1- to 5-day  
636 period after inoculation. Last pie chart in the series for each participant refers to the study  
637 treatment day when clinical urethritis was apparent and/or when antibiotic treatment was  
638 administered.

## 639 Bibliography

- 640 1. Maness MJ, and Sparling PF. Multiple antibiotic resistance due to a single mutation in  
641 *Neisseria gonorrhoeae*. *J Infect Dis*. 1973;128(3):321-30.
- 642 2. Guymon LF, Walstad DL, and Sparling PF. Cell envelope alterations in antibiotic-  
643 sensitive and-resistant strains of *Neisseria gonorrhoeae*. *J Bacteriol*. 1978;136(1):391-  
644 401.
- 645 3. Shafer WM, Qu X, Waring AJ, et al. Modulation of *Neisseria gonorrhoeae* susceptibility  
646 to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division  
647 efflux pump family. *Proc Natl Acad Sci U S A*. 1998;95(4):1829-33.
- 648 4. Hagman KE, Lucas CE, Balthazar JT, et al. The MtrD protein of *Neisseria gonorrhoeae* is  
649 a member of the resistance/nodulation/division protein family constituting part of an  
650 efflux system. *Microbiology (Reading)*. 1997;143 ( Pt 7):2117-25.
- 651 5. Lucas CE, Hagman KE, Levin JC, et al. Importance of lipooligosaccharide structure in  
652 determining gonococcal resistance to hydrophobic antimicrobial agents resulting from the  
653 mtr efflux system. *Mol Microbiol*. 1995;16(5):1001-9.
- 654 6. Hagman KE, Pan W, Spratt BG, et al. Resistance of *Neisseria gonorrhoeae* to  
655 antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system.  
656 *Microbiology (Reading)*. 1995;141 ( Pt 3):611-22.
- 657 7. Lucas CE, Balthazar JT, Hagman KE, et al. The MtrR repressor binds the DNA sequence  
658 between the mtrR and mtrC genes of *Neisseria gonorrhoeae*. *J Bacteriol*.  
659 1997;179(13):4123-8.
- 660 8. Warner DM, Shafer WM, and Jerse AE. Clinically relevant mutations that cause  
661 derepression of the *Neisseria gonorrhoeae* MtrC-MtrD-MtrE Efflux pump system confer  
662 different levels of antimicrobial resistance and in vivo fitness. *Mol Microbiol*.  
663 2008;70(2):462-78.
- 664 9. Lyu M, Ayala JC, Chirakos I, et al. Structural Basis of Peptide-Based Antimicrobial  
665 Inhibition of a Resistance-Nodulation-Cell Division Multidrug Efflux Pump. *Microbiol*  
666 *Spectr*. 2022;10(5):e0299022.
- 667 10. Delahay RM, Robertson BD, Balthazar JT, et al. Involvement of the gonococcal MtrE  
668 protein in the resistance of *Neisseria gonorrhoeae* to toxic hydrophobic agents.  
669 *Microbiology (Reading)*. 1997;143 ( Pt 7):2127-33.
- 670 11. Handing JW, Ragland SA, Bharathan UV, et al. The MtrCDE Efflux Pump Contributes  
671 to Survival of *Neisseria gonorrhoeae* From Human Neutrophils and Their Antimicrobial  
672 Components. *Front Microbiol*. 2018;9:2688.
- 673 12. Hagman KE, and Shafer WM. Transcriptional control of the mtr efflux system of  
674 *Neisseria gonorrhoeae*. *J Bacteriol*. 1995;177(14):4162-5.
- 675 13. Shafer WM, Balthazar JT, Hagman KE, et al. Missense mutations that alter the DNA-  
676 binding domain of the MtrR protein occur frequently in rectal isolates of *Neisseria*  
677 *gonorrhoeae* that are resistant to faecal lipids. *Microbiology (Reading)*. 1995;141 ( Pt  
678 4):907-11.
- 679 14. Janganan TK, Zhang L, Bavro VN, et al. Opening of the outer membrane protein channel  
680 in tripartite efflux pumps is induced by interaction with the membrane fusion partner. *J*  
681 *Biol Chem*. 2011;286(7):5484-93.
- 682 15. Bolla JR, Su CC, Do SV, et al. Crystal structure of the *Neisseria gonorrhoeae* MtrD inner  
683 membrane multidrug efflux pump. *PLoS One*. 2014;9(6):e97903.

- 684 16. Hoffmann KM, Williams D, Shafer WM, et al. Characterization of the multiple  
685 transferable resistance repressor, MtrR, from *Neisseria gonorrhoeae*. *J Bacteriol.*  
686 2005;187(14):5008-12.
- 687 17. Zalucki YM, Dhulipala V, and Shafer WM. Dueling regulatory properties of a  
688 transcriptional activator (MtrA) and repressor (MtrR) that control efflux pump gene  
689 expression in *Neisseria gonorrhoeae*. *mBio.* 2012;3(6):e00446-12.
- 690 18. Rouquette C, Harmon JB, and Shafer WM. Induction of the mtrCDE-encoded efflux  
691 pump system of *Neisseria gonorrhoeae* requires MtrA, an AraC-like protein. *Mol*  
692 *Microbiol.* 1999;33(3):651-8.
- 693 19. Jerse AE, Sharma ND, Simms AN, et al. A gonococcal efflux pump system enhances  
694 bacterial survival in a female mouse model of genital tract infection. *Infect Immun.*  
695 2003;71(10):5576-82.
- 696 20. Rouquette-Loughlin CE, Reimche JL, Balthazar JT, et al. Mechanistic Basis for  
697 Decreased Antimicrobial Susceptibility in a Clinical Isolate of *Neisseria gonorrhoeae*  
698 Possessing a Mosaic-Like mtr Efflux Pump Locus. *mBio.* 2018;9(6).
- 699 21. Veal WL, Yellen A, Balthazar JT, et al. Loss-of-function mutations in the mtr efflux  
700 system of *Neisseria gonorrhoeae*. *Microbiology (Reading).* 1998;144 ( Pt 3):621-7.
- 701 22. Veal WL, Nicholas RA, and Shafer WM. Overexpression of the MtrC-MtrD-MtrE efflux  
702 pump due to an mtrR mutation is required for chromosomally mediated penicillin  
703 resistance in *Neisseria gonorrhoeae*. *J Bacteriol.* 2002;184(20):5619-24.
- 704 23. Ohneck EA, Zalucki YM, Johnson PJ, et al. A novel mechanism of high-level, broad-  
705 spectrum antibiotic resistance caused by a single base pair change in *Neisseria*  
706 *gonorrhoeae*. *mBio.* 2011;2(5).
- 707 24. Warner DM, Folster JP, Shafer WM, et al. Regulation of the MtrC-MtrD-MtrE efflux-  
708 pump system modulates the in vivo fitness of *Neisseria gonorrhoeae*. *J Infect Dis.*  
709 2007;196(12):1804-12.
- 710 25. Golparian D, Shafer WM, Ohnishi M, et al. Importance of multidrug efflux pumps in the  
711 antimicrobial resistance property of clinical multidrug-resistant isolates of *Neisseria*  
712 *gonorrhoeae*. *Antimicrob Agents Chemother.* 2014;58(6):3556-9.
- 713 26. Ohnishi M, Golparian D, Shimuta K, et al. Is *Neisseria gonorrhoeae* initiating a future era  
714 of untreatable gonorrhea?: detailed characterization of the first strain with high-level  
715 resistance to ceftriaxone. *Antimicrob Agents Chemother.* 2011;55(7):3538-45.
- 716 27. Hobbs MM, Sparling PF, Cohen MS, et al. Experimental Gonococcal Infection in Male  
717 Volunteers: Cumulative Experience with *Neisseria gonorrhoeae* Strains FA1090 and  
718 MS11mkC. *Front Microbiol.* 2011;2:123.
- 719 28. Waltmann A DJ, Pier GB, Cywes-Bentley C, Cohen MC, Hobbs MM. In: Fabio Bagnoli  
720 GDG, Sanjay K. Phogat, Rino Rappuoli ed. *Human Challenge Studies for Vaccine*  
721 *Development.* Springer Nature; 2021.
- 722 29. Hobbs MM, Anderson JE, Balthazar JT, et al. Lipid A's structure mediates *Neisseria*  
723 *gonorrhoeae* fitness during experimental infection of mice and men. *mBio.*  
724 2013;4(6):e00892-13.
- 725 30. Jerse AE. Experimental gonococcal genital tract infection and opacity protein expression  
726 in estradiol-treated mice. *Infect Immun.* 1999;67(11):5699-708.
- 727 31. Feinen B, Jerse AE, Gaffen SL, et al. Critical role of Th17 responses in a murine model  
728 of *Neisseria gonorrhoeae* genital infection. *Mucosal Immunol.* 2010;3(3):312-21.



- 729 32. Jerse AE, Wu H, Packiam M, et al. Estradiol-Treated Female Mice as Surrogate Hosts for  
730 *Neisseria gonorrhoeae* Genital Tract Infections. *Front Microbiol.* 2011;2:107.
- 731 33. Jerse AE, Crow ET, Bordner AN, et al. Growth of *Neisseria gonorrhoeae* in the female  
732 mouse genital tract does not require the gonococcal transferrin or hemoglobin receptors  
733 and may be enhanced by commensal lactobacilli. *Infect Immun.* 2002;70(5):2549-58.
- 734 34. Soler-Garcia AA, and Jerse AE. *Neisseria gonorrhoeae* catalase is not required for  
735 experimental genital tract infection despite the induction of a localized neutrophil  
736 response. *Infect Immun.* 2007;75(5):2225-33.
- 737 35. Muench DF, Kuch DJ, Wu H, et al. Hydrogen peroxide-producing lactobacilli inhibit  
738 gonococci in vitro but not during experimental genital tract infection. *J Infect Dis.*  
739 2009;199(9):1369-78.
- 740 36. Song W, Condron S, Mocca BT, et al. Local and humoral immune responses against  
741 primary and repeat *Neisseria gonorrhoeae* genital tract infections of 17beta-estradiol-  
742 treated mice. *Vaccine.* 2008;26(45):5741-51.
- 743 37. Leduc I, Connolly KL, Begum A, et al. The serogroup B meningococcal outer membrane  
744 vesicle-based vaccine 4CMenB induces cross-species protection against *Neisseria*  
745 *gonorrhoeae*. *PLoS Pathog.* 2020;16(12):e1008602.
- 746 38. Ma KC, Mortimer TD, Hicks AL, et al. Adaptation to the cervical environment is  
747 associated with increased antibiotic susceptibility in *Neisseria gonorrhoeae*. *Nat*  
748 *Commun.* 2020;11(1):4126.
- 749 39. Nachamkin I, Cannon JG, and Mittler RS. Monoclonal antibodies against *Neisseria*  
750 *gonorrhoeae*: production of antibodies directed against a strain-specific cell surface  
751 antigen. *Infect Immun.* 1981;32(2):641-8.
- 752 40. Lyu M, Moseng MA, Reimche JL, et al. Cryo-EM Structures of a Gonococcal Multidrug  
753 Efflux Pump Illuminate a Mechanism of Drug Recognition and Resistance. *mBio.*  
754 2020;11(3).
- 755 41. Barnes PD, Bergman MA, Meccas J, et al. *Yersinia pseudotuberculosis* disseminates  
756 directly from a replicating bacterial pool in the intestine. *J Exp Med.* 2006;203(6):1591-  
757 601.
- 758 42. Brown SP, Cornell SJ, Sheppard M, et al. Intracellular demography and the dynamics of  
759 *Salmonella enterica* infections. *PLoS Biol.* 2006;4(11):e349.
- 760 43. Gerlini A, Colomba L, Furi L, et al. The role of host and microbial factors in the  
761 pathogenesis of pneumococcal bacteraemia arising from a single bacterial cell bottleneck.  
762 *PLoS Pathog.* 2014;10(3):e1004026.
- 763 44. Grant AJ, Restif O, McKinley TJ, et al. Modelling within-host spatiotemporal dynamics  
764 of invasive bacterial disease. *PLoS Biol.* 2008;6(4):e74.
- 765 45. Moxon ER, and Murphy PA. *Haemophilus influenzae* bacteremia and meningitis  
766 resulting from survival of a single organism. *Proc Natl Acad Sci U S A.* 1978;75(3):1534-  
767 6.
- 768 46. Sheppard M, Webb C, Heath F, et al. Dynamics of bacterial growth and distribution  
769 within the liver during *Salmonella* infection. *Cell Microbiol.* 2003;5(9):593-600.
- 770 47. Joseph SB, Swanstrom R, Kashuba AD, et al. Bottlenecks in HIV-1 transmission:  
771 insights from the study of founder viruses. *Nat Rev Microbiol.* 2015;13(7):414-25.
- 772 48. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of  
773 transmitted and early founder virus envelopes in primary HIV-1 infection. *Proc Natl*  
774 *Acad Sci U S A.* 2008;105(21):7552-7.

- 775 49. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-  
776 sensitive HIV-1 after heterosexual transmission. *Science*. 2004;303(5666):2019-22.
- 777 50. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection  
778 with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution  
779 of transmitted variants. *J Virol*. 2009;83(8):3556-67.
- 780 51. Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al. Inflammatory genital infections  
781 mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C  
782 HIV-1. *PLoS Pathog*. 2009;5(1):e1000274.
- 783 52. Lovett A, and Duncan JA. Human Immune Responses and the Natural History of  
784 *Neisseria gonorrhoeae* Infection. *Front Immunol*. 2018;9:3187.
- 785 53. Ercoli G, Fernandes VE, Chung WY, et al. Intracellular replication of *Streptococcus*  
786 *pneumoniae* inside splenic macrophages serves as a reservoir for septicemia. *Nat*  
787 *Microbiol*. 2018;3(5):600-10.
- 788 54. Kono M, Zafar MA, Zuniga M, et al. Single Cell Bottlenecks in the Pathogenesis of  
789 *Streptococcus pneumoniae*. *PLoS Pathog*. 2016;12(10):e1005887.
- 790 55. Zafar MA, Kono M, Wang Y, et al. Infant Mouse Model for the Study of Shedding and  
791 Transmission during *Streptococcus pneumoniae* Monoinfection. *Infect Immun*.  
792 2016;84(9):2714-22.
- 793 56. Liu X, Kimmey JM, Matarazzo L, et al. Exploration of Bacterial Bottlenecks and  
794 *Streptococcus pneumoniae* Pathogenesis by CRISPRi-Seq. *Cell Host Microbe*.  
795 2021;29(1):107-20 e6.
- 796 57. Hadad R, Jacobsson S, Pizza M, et al. Novel meningococcal 4CMenB vaccine antigens -  
797 prevalence and polymorphisms of the encoding genes in *Neisseria gonorrhoeae*. *APMIS*.  
798 2012;120(9):750-60.
- 799 58. Marjuki H, Topaz N, Joseph SJ, et al. Genetic Similarity of Gonococcal Homologs to  
800 Meningococcal Outer Membrane Proteins of Serogroup B Vaccine. *mBio*. 2019;10(5).
- 801 59. Perrin A, Bonacorsi S, Carbonnelle E, et al. Comparative genomics identifies the genetic  
802 islands that distinguish *Neisseria meningitidis*, the agent of cerebrospinal meningitis,  
803 from other *Neisseria* species. *Infect Immun*. 2002;70(12):7063-72.
- 804 60. Tinsley CR, and Nassif X. Analysis of the genetic differences between *Neisseria*  
805 *meningitidis* and *Neisseria gonorrhoeae*: two closely related bacteria expressing two  
806 different pathogenicities. *Proc Natl Acad Sci U S A*. 1996;93(20):11109-14.
- 807 61. Bayliss CD, Hoe JC, Makepeace K, et al. *Neisseria meningitidis* escape from the  
808 bactericidal activity of a monoclonal antibody is mediated by phase variation of IgtG and  
809 enhanced by a mutator phenotype. *Infect Immun*. 2008;76(11):5038-48.
- 810 62. Banerjee A, Wang R, Uljon SN, et al. Identification of the gene (IgtG) encoding the  
811 lipooligosaccharide beta chain synthesizing glucosyl transferase from *Neisseria*  
812 *gonorrhoeae*. *Proc Natl Acad Sci U S A*. 1998;95(18):10872-7.
- 813 63. Shafer WM, Datta A, Kolli VS, et al. Phase variable changes in genes IgtA and IgtC  
814 within the IgtABCDE operon of *Neisseria gonorrhoeae* can modulate gonococcal  
815 susceptibility to normal human serum. *J Endotoxin Res*. 2002;8(1):47-58.
- 816 64. Gulati S, Zheng B, Reed GW, et al. Immunization against a saccharide epitope  
817 accelerates clearance of experimental gonococcal infection. *PLoS Pathog*.  
818 2013;9(8):e1003559.
- 819 65. Gulati S, Beurskens FJ, de Kreuk BJ, et al. Complement alone drives efficacy of a  
820 chimeric antigonococcal monoclonal antibody. *PLoS Biol*. 2019;17(6):e3000323.

- 821 66. Golubchik T, Batty EM, Miller RR, et al. Within-host evolution of *Staphylococcus*  
822 *aureus* during asymptomatic carriage. *PLoS One*. 2013;8(5):e61319.
- 823 67. Jerse AE, Cohen MS, Drown PM, et al. Multiple gonococcal opacity proteins are  
824 expressed during experimental urethral infection in the male. *J Exp Med*.  
825 1994;179(3):911-20.
- 826 68. Seifert HS, Wright CJ, Jerse AE, et al. Multiple gonococcal pilin antigenic variants are  
827 produced during experimental human infections. *J Clin Invest*. 1994;93(6):2744-9.
- 828 69. Wright CJ, Jerse AE, Cohen MS, et al. Nonrepresentative PCR amplification of variable  
829 gene sequences in clinical specimens containing dilute, complex mixtures of  
830 microorganisms. *J Clin Microbiol*. 1994;32(2):464-8.
- 831 70. Hamrick TS, Dempsey JAF, Cohen MS, et al. Antigenic variation of gonococcal pilin  
832 expression in vivo: analysis of the strain FA1090 pilin repertoire and identification of the  
833 pilS gene copies recombining with pilE during experimental human infection.  
834 *Microbiology (Reading)*. 2001;147(Pt 4):839-49.
- 835 71. Gor V, Ohniwa RL, and Morikawa K. No Change, No Life? What We Know about Phase  
836 Variation in *Staphylococcus aureus*. *Microorganisms*. 2021;9(2).
- 837 72. Aidley J, Rajopadhye S, Akinyemi NM, et al. Nonselective Bottlenecks Control the  
838 Divergence and Diversification of Phase-Variable Bacterial Populations. *mBio*.  
839 2017;8(2).
- 840 73. Libby E, and Rainey PB. Exclusion rules, bottlenecks and the evolution of stochastic  
841 phenotype switching. *Proc Biol Sci*. 2011;278(1724):3574-83.
- 842 74. Palmer ME, Lipsitch M, Moxon ER, et al. Broad conditions favor the evolution of phase-  
843 variable loci. *mBio*. 2013;4(1):e00430-12.
- 844 75. Moxon R, and Kussell E. The impact of bottlenecks on microbial survival, adaptation,  
845 and phenotypic switching in host-pathogen interactions. *Evolution*. 2017;71(12):2803-16.
- 846 76. Abraham SN, and Miao Y. The nature of immune responses to urinary tract infections.  
847 *Nat Rev Immunol*. 2015;15(10):655-63.
- 848 77. Pudney J, and Anderson D. Innate and acquired immunity in the human penile urethra. *J*  
849 *Reprod Immunol*. 2011;88(2):219-27.
- 850 78. Abel S, Abel zur Wiesch P, Davis BM, et al. Analysis of Bottlenecks in Experimental  
851 Models of Infection. *PLoS Pathog*. 2015;11(6):e1004823.
- 852 79. Qu J, Prasad NK, Yu MA, et al. Modulating Pathogenesis with Mobile-CRISPRi. *J*  
853 *Bacteriol*. 2019;201(22).
- 854 80. Garvin LE, Bash MC, Keys C, et al. Phenotypic and genotypic analyses of *Neisseria*  
855 *gonorrhoeae* isolates that express frequently recovered PorB PIA variable region types  
856 suggest that certain P1a porin sequences confer a selective advantage for urogenital tract  
857 infection. *Infect Immun*. 2008;76(8):3700-9.
- 858 81. Johnston DM, and Cannon JG. Construction of mutant strains of *Neisseria gonorrhoeae*  
859 lacking new antibiotic resistance markers using a two gene cassette with positive and  
860 negative selection. *Gene*. 1999;236(1):179-84.
- 861 82. Cohen MS, Cannon JG, Jerse AE, et al. Human experimentation with *Neisseria*  
862 *gonorrhoeae*: rationale, methods, and implications for the biology of infection and  
863 vaccine development. *J Infect Dis*. 1994;169(3):532-7.
- 864 83. Cornelissen CN, Kelley M, Hobbs MM, et al. The transferrin receptor expressed by  
865 gonococcal strain FA1090 is required for the experimental infection of human male  
866 volunteers. *Mol Microbiol*. 1998;27(3):611-6.

- 867 84. Raterman EL, and Jerse AE. Female Mouse Model of *Neisseria gonorrhoeae* Infection.  
868 *Methods Mol Biol.* 2019;1997:413-29.
- 869 85. Dillard JP. Genetic Manipulation of *Neisseria gonorrhoeae*. *Curr Protoc Microbiol.*  
870 2011;Chapter 4:Unit4A 2.
- 871 86. Mickelsen PA, and Sparling PF. Ability of *Neisseria gonorrhoeae*, *Neisseria meningitidis*,  
872 and commensal *Neisseria* species to obtain iron from transferrin and iron compounds.  
873 *Infect Immun.* 1981;33(2):555-64.  
874